ALK-Abelló (CPSE:ALK B) Lifted Guidance And Won NICE Backing, Is It Cheap?

ALK-Abelló (CPSE:ALK B) is in focus after reporting higher year on year sales and net income for the second quarter of 2026, slightly raising full year revenue guidance, and securing new NICE recommendations in the UK.

At a share price of DKK210.2, ALK-Abelló has seen the 90 day share price return fall 20.74% and the 30 day share price return decline 6.83%. This is the case even though the 1 year total shareholder return is 6.22% and the 3 year total shareholder return is about 2.6x, suggesting longer term holders have still seen gains despite more recent pressure linked to shifting expectations after earnings, guidance and the new UK treatment recommendations.

Compare ALK-Abelló's recent momentum shift with other hand picked healthcare stocks by scanning the 134 healthcare AI stocks that are catching investors' attention right now.

So is ALK-Abelló's pullback after stronger earnings and higher guidance really about cracks in the business, or has sentiment simply swung too far in the short term, given the new UK treatment backing and recent returns?

Most Popular Narrative: 29.3% Undervalued

ALK-Abelló's most followed narrative sees fair value at DKK297.50 compared with the last close at DKK210.20, which frames the recent pullback very differently from the headline price moves.

Recent successful launches and positive momentum for pediatric indications of ACARIZAX and ITULAZAX respiratory tablets are expanding ALK-Abelló's addressable patient pool among children and adolescents, a segment with increasing allergy prevalence globally, supporting sustained top-line revenue growth as these products gain market share.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that fair value for ALK-Abelló? The narrative leans heavily on accelerating tablet adoption, expanding indications and a richer earnings profile over time. Curious how those moving parts translate into the current DKK figure and pricing gap.

Result: Fair Value of DKK297.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ALK-Abelló's reliance on a relatively narrow allergy portfolio, along with the successful uptake of products like neffy, means regulatory setbacks or slower adoption could quickly challenge that undervalued narrative.

Find out about the key risks to this ALK-Abelló narrative.

Another View On ALK-Abelló's Valuation

While the most popular ALK-Abelló narrative leans on a fair value of DKK297.50, the current multiples tell a different story. The stock trades on a P/E of 34.4x compared with a fair ratio of 18.6x, the European pharmaceuticals average of 21.7x and peer average of 14.5x. That is a wide gap, which points to real valuation risk if sentiment cools, so which signal do you trust more today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of confidence and caution around ALK-Abelló has you thinking, now is a good time to inspect the data yourself and stress test the story against your own expectations. To see why some investors are still optimistic, review the 3 key rewards.

Looking for more investment ideas beyond ALK-Abelló?

If ALK-Abelló has sharpened your focus, do not stop here. Broaden your watchlist with high quality ideas filtered by balance sheet strength, value and income potential.

• Target resilient companies that can better handle shocks by scanning a list of solid balance sheet and fundamentals (426 results) that keeps financial strength front and center.
• Hunt for potential value opportunities before they are widely followed using a curated 611 high quality undiscovered gems built around strong fundamentals.
• Build a portfolio with income in mind by reviewing a focused 411 dividend fortresses that highlights higher yielding stocks with an emphasis on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com